-
-
yesterday 14:38
-
-
-
-
-
-
-
-
-
-
-
Favipiravir permanently registered in Russia for COVID-19 treatment

MOSCOW. KAZINFORM - Favipiravir, a drug used to treat COVID-19, has received permanent registration in Russia, Russian Deputy Health Minister Viktor Fisenko said on Thursday, TASS reports.
«Following a sped-up procedure, we have greenlit circulation of prevention drugs (vaccines), antiviral therapy drugs - Favipiravir, Remdesivir, and a drug used to mitigate a cytokine storm - Levilimab,» he said, adding that Favipiravir has received a permanent registration certificate.
Earlier, the Russian Federal Service for Surveillance in Healthcare informed that Russia had registered three drugs based on Favipiravir: Avifavir, Areplivir and Coronavir. The watchdog has not received any complaints of non-specific motor disorders during the use of the drugs.
- New virus cases in 500s for 6th day; tougher curbs partially eased in S. Korea
- Olympics: Japan scrambles to deny reports that cancelation possible
- Beijing sees high COVID-19 vaccine uptake in service sectors
- 294 COVID-19 patients in critical condition in Kazakhstan
-
COVID-19: Atyrau and Pavlodar regions move into ‘red zone’
-
WHO report over 688,000 new daily cases of COVID-19
- Speeches of the President of the Republic of Kazakhstan
- President's Address to the Nation
- Development of the President's Message
- Foreign Mass Media about Kazakhstan
- World and Crisis